What Promogran Treats: Main Uses and Benefits

The Promogran matrix is relevant in the management of complex, non-healing wounds, and is used in areas where additional symptomatic support is needed. The dressing is indicated for the management of exuding wounds.

Addressing Stalled Chronic Wounds

This product is commonly used in clinical situations involving stalled wounds—ulcers that have failed to progress toward healing—including deep full-thickness and partial-thickness lesions. The intervention may assist with the symptom cluster that interferes with daily functioning and contributes to easing the overall symptom load. The specific chronic wound categories it is relevant for easing include Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Injuries (Ulcers), and dehisced surgical wounds.

Quick Fact: Support for Non-Progressing Wounds The matrix is applied when appropriate in contexts involving hard-to-heal wounds that require supportive symptom management to promote functional stability.

Supporting Symptomatic Management

The product's therapeutic domain is applied across domains where additional symptomatic support is needed in conditions marked by impaired healing. For the patient, this provides support that helps ease the overall symptom burden associated with persistent open wounds, assisting the affected area with managing the conditions where functional stability becomes affected.

This specialized matrix may be part of symptomatic management in situations where symptoms create noticeable physiological strain and require supportive symptom management to promote functional stability.

Regulatory References

1. U.S. Food and Drug Administration (FDA) 510(k) Premarket Notification

Who Can and Cannot Use Promogran?

The eligibility for using Promogran Matrix is determined by its official regulatory label, focusing primarily on known patient allergies and the specific condition of the wound.

---

Absolute Contraindications

The Promogran Matrix and Promogran Prisma Matrix are absolutely contraindicated (must not be used) in patients with a documented hypersensitivity or allergy to its core components: Collagen or Oxidized Regenerated Cellulose (ORC). For the silver-containing Promogran Prisma, known sensitivity to silver is also a contraindication. Use is further prohibited on specific non-eligible wound types, including third-degree burns and wounds with active vasculitis.

---

Restricted and Conditional Use

The matrix is generally allowed for use in patients with exuding wounds, such as Diabetic, Venous, and Pressure Ulcers. However, use is conditional on the preparation of the wound bed. The matrix must only be applied after all necrotic tissue has been removed. If visible signs of infection are present, the product must be used only in conjunction with appropriate systemic antimicrobial therapy. Regulatory data notes that there is limited information regarding the prolonged or repeated use of the silver-containing variant in children and neonates. No specific restrictions related to systemic conditions, such as hepatic or renal impairment, or for use during pregnancy, are documented in the official labeling.

Interactions with other medicines and products

Promogran is a specialized, bioresorbable matrix for wound care that is applied topically, consisting of Collagen and Oxidized Regenerated Cellulose (ORC). Due to its local application and negligible systemic absorption, official regulatory documents do not report any systemic pharmacokinetic (PK) or pharmacodynamic (PD) interactions with orally administered or injected medicines, food, alcohol, or dietary supplements.

Documented Topical Substance Incompatibilities

The officially documented interactions for this product are specific to chemical and physical incompatibilities with other topical agents at the wound site, leading to mandatory usage restrictions.

Restricted Co-Administration	Constraint Defined in Regulatory Labels
Enzymatic debriding agents	Restricted from concurrent use; these agents may chemically degrade the collagen component of the matrix.
Heavy metal-containing solutions	Mandatory pre-application removal is required; solutions such as silver nitrate must be completely removed by irrigation before the dressing is applied.

These constraints define the regulatory-based limitations for combining the matrix with other local wound care substances. No population-specific interaction considerations are documented for use in patients with conditions such as hepatic or renal impairment.

The Promogran matrix operates through local Extracellular Matrix (ECM) Modulation by chemically altering the enzymatic balance at the application site. The mechanism of action is confined to the application site; the matrix components do not exert systemic pharmacological activity.

Enzyme Sequestration and Neutralization

This domain addresses the matrix's core molecular interaction. The Oxidized Regenerated Cellulose (ORC) component forms a gel that actively binds and sequesters excessive concentrations of key enzymes, primarily Matrix Metalloproteinases (MMPs), which drive tissue degradation. This neutralizing action interrupts the excessive proteolytic cascade, thereby altering the destructive molecular cycle.

Growth Factor Protection and Structural Scaffolding

This mechanism facilitates the processes of tissue regeneration. Reducing protease presence results in the preservation of endogenous Growth Factors (e.g., PDGF, FGF) and native structural proteins from enzymatic degradation. Simultaneously, the Collagen component provides an ideal structural scaffold for cells to attach to, supporting the physiological processes of cell migration and granulation tissue formation.

Modulating the Catabolic-Anabolic Shift

The synergistic action of protease neutralization and structural support drives a critical physiological change. The mechanism induces a local shift from an environment dominated by catabolic activity to one favoring anabolic activity. This shift represents the core physiological consequence, promoting conditions necessary for tissue regeneration.

How Promogran is Used: Administration Guidelines

Administration Scope and Frequency

The Promogran matrix is indicated for topical application, placed directly onto the prepared wound surface. Unlike systemic medications, the administration “dose” is determined not by mass but by the wound surface area; one single-use matrix is applied and must be trimmed to the exact size of the affected site. Reapplication frequency is typically scheduled every two to three days (48 to 72 hours), a pattern determined by clinical assessment of the rate of matrix degradation and exudate volume. As a non-systemic product, no systemic dose adjustments are specified for considerations such as older age or renal/hepatic impairment.

Preparation and Procedural Conditions

Standard application involves specific preparation steps. Prior to application, the wound bed must undergo complete debridement to remove all non-viable tissue. The lyophilized matrix requires hydration with a sterile solution before or immediately following placement to convert it into an effective gel. The complete procedure requires an aseptic technique and the application must be secured with a secondary dressing to maintain appropriate wound conditions. The use is maintained until the wound achieves a state of robust granulation, with the duration guided by clinical assessment rather than a fixed treatment cycle.

Research evidence / Overview of Studies for Promogran

This section outlines the structure of the clinical research that has evaluated the use of Promogran (a matrix composed of collagen and oxidized regenerated cellulose) in the management of chronic wounds. This overview describes the types of studies conducted, the specific outcomes monitored by researchers, and areas where evidence remains limited, without offering any clinical interpretation or guidance.

---

Evidence for use in Diabetic Foot Ulcers (DFUs)

Research for Diabetic Foot Ulcers primarily consists of Randomized Controlled Trials (RCTs), including large multicenter studies, which were then summarized in meta-analyses. The research examined the product alongside standard care. The outcomes tracked were related to the measurement of wound closure, specifically achieving complete wound closure, the time monitored for healing, and the percentage of wound size reduction. One large RCT reported that the primary endpoint of complete wound closure was not consistently differentiated from the control group across the entire study population. However, subsequent analyses have described patterns in measured closure rates in specific patient subgroups.

---

Evidence for use in Venous Leg Ulcers (VLUs) and Pressure Injuries (PIs/PUs)

The research for Venous Leg Ulcers was studied for conditions marked by functional limitations. The matrix was evaluated in studies where it was used as an adjunct to standard compression therapy. The main limitation here is that comparative evidence is lacking to fully isolate the individual contribution of the matrix itself when used alongside standard treatments. For Pressure Injuries, the available research base includes a limited number of comparative RCTs, and the certainty remains low given the modest sample sizes in the controlled studies available.

---

Study Gaps and Areas of Uncertainty

Findings were mixed regarding the primary outcome in the overall population of the largest DFU trials. Furthermore, long-term outcomes are not fully established for any of the indications, as follow-up durations were limited across the major RCTs. Comparative evidence is lacking to isolate the full effect of the matrix when it is used alongside standard treatments, and data for certain groups remain insufficient.

Key Studies & References Guidance on the use of Promogran and Promogran Prisma for treating diabetic foot ulcers and venous leg ulcers (NICE MTG49)

Common questions about Promogran (FAQ)

Q: How long does a single application of Promogran usually last?

Official regulatory documents indicate that the Promogran matrix is typically reapplied every two to three days (48 to 72 hours). The reapplication schedule is determined by the healthcare professional based on a clinical assessment of the rate of matrix degradation and the wound fluid present.

Q: Can Promogran be cut or trimmed to fit a certain area?

Official regulatory protocols describe that the single-use matrix should be trimmed to the exact size of the affected wound site to ensure proper contact and function.

Q: Can I go swimming or shower while using Promogran?

The Promogran matrix requires securing with a secondary dressing to maintain appropriate wound conditions. Regulatory information does not specifically address swimming or showering; management of water exposure is generally guided by the instructions for the required secondary dressing, which maintains appropriate wound conditions.

Q: Is Promogran considered a type of antibiotic?

Promogran is officially classified as an Advanced Wound Care Product and an Extracellular Matrix Modulator. The base product is not described as a traditional antibiotic drug. However, a variant of the product, Promogran Prisma, includes ionically bound silver, which is described as an antimicrobial agent.

Q: Can Promogran be used on children?

Regulatory data notes that there is limited information regarding the prolonged or repeated use of the silver-containing variant, Promogran Prisma, in children and neonates. The official labeling focuses on this limitation rather than providing specific instructions for the standard matrix in this population.

Q: Are there any common long-term concerns about using Promogran?

Regulatory analysis of the research indicates that long-term outcomes are not fully established for any of the indications, due to limited follow-up durations in the major studies.

Q: Are there any foods or supplements that interact with Promogran?

Official regulatory documents do not report any systemic interactions between the matrix and orally administered medicines, food, alcohol, or dietary supplements. This is due to its local application on the wound and negligible absorption into the body.

Q: Is Promogran the same as Promogran Prisma?

No, Promogran Prisma is a specific variation of the Promogran matrix that includes an additional component: ionically bound silver. The standard matrix does not contain silver. The silver variant carries an additional contraindication for patients with known silver sensitivity.

Q: How is the effectiveness of Promogran measured in studies?

Clinical research evaluating the matrix primarily measures outcomes related to wound healing. These typically include the measurement of complete wound closure, the time monitored for healing, and the percentage of wound size reduction over the study period.

Official Storage Requirements

Promogran is a sterile, lyophilized matrix dressing, and its storage is primarily governed by the need to maintain product sterility and stability. Official regulatory information dictates that the matrix must be stored in a cool, dry place, and extremes of temperature should be avoided to prevent degradation. It is mandatory to keep the product within its original sealed packaging until the moment of application to ensure its status as a sterile dressing (FDA 510(k) Summary).

Handling and Disposal Instructions

Due to its composition, the Promogran matrix is not classified as hazardous and does not require special environmental precautions beyond standard sterile working procedures. For disposal, unused or expired dressings must be discarded according to local and national regulations. Used dressings should be collected and handled as clinical waste (Safety Data Sheet, SDS).